CD274 and neoplasm: For mTNBC maintenance therapy, the phase II/III KEYLYNK-009 study found pembrolizumab plus olaparib as maintenance therapy did not lead to a notable enhancement in PFS and OS compared with pembrolizumab plus chemotherapy, including those with a PD-L1 CPS ≥10 and tumor BRCA mutations (tBRCAm).